ISSN: 0264-410X

Journal Home

Journal Guideline

Vaccine Q1 Unclaimed

Elsevier BV Netherlands

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Vaccine is a journal indexed in SJR in Infectious Diseases and Molecular Medicine with an H index of 175. It has a price of 2395 €. It has an SJR impact factor of 1,683 and it has a best quartile of Q1. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Immunology and Microbiology (miscellaneous) (Q1) Infectious Diseases (Q1) Molecular Medicine (Q1) Public Health, Environmental and Occupational Health (Q1) Veterinary (miscellaneous) (Q1)

Price

2395 €

Gold OA

-

Green OA

0 €

Non OA

Metrics

1,683

SJR Impact factor

175

H Index

1046

Total Docs (Last Year)

3135

Total Docs (3 years)

38978

Total Refs

10094

Total Cites (3 years)

2889

Citable Docs (3 years)

3,37

Cites/Doc (2 years)

37,26

Ref/Doc

Aims and Scope

Other journals with similar parameters

The Lancet Infectious Diseases Q1
Clinical Microbiology Reviews Q1
Microbiology and Molecular Biology Reviews Q1
The Lancet HIV Q1
FEMS Microbiology Reviews Q1

Best articles

A look at new models to support vaccine research and development

A model to estimate the potential economic benefits of measles eradication for the United States

A possible explanation for the discrepancy between ELISA and neutralising antibodies to tetanus toxin

Alkyl-polyacrylate esters are strong mucosal adjuvants

An editorial policy statement

Analysis of factors influencing vaccine uptake from various perspectives

Analysis of factors influencing vaccine uptake: perspective from Spain

Analysis of factors influencing vaccine uptake: perspectives from Belgium

Analysis of recombinant mouse zona pellucida protein 2 (ZP2) constructs for immunocontraception

Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines

Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases

Antigen receptors and dendritic cells

SHOW MORE ARTICLES

Benefit and risk of vaccination as seen by the general public and the media

Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose

Business perspectives of a European vaccine manufacturer

CHILD Profile: an immunization registry and more--a new approach to tracking and surveillance

Comparison of the safety and immunogenicity of the lyophilized Merieux seed and the World Health Organization working reference BCG vaccines in school-aged children in Senegal

Cost-effectiveness of hepatitis A and B vaccination programme in Germany

Detection of adverse events: what are the current sensitivity limits during clinical development?

Developing vaccines involving new technologies to ensure safety and timely licensure

Development of a transgenic mouse neurovirulence test for oral poliovirus vaccine: international collaborative study 1993-1999

DNA pulsed macrophage-mediated cDNA expression library immunization in vaccine development

Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA¬Æ

Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply

Comments

No comments ... Be the first to comment!

Publication speed

Review quality

Edition and editorial team

Paper Link

Attach one of your papers. We need to confirm that you have had a relation with this journal in order to review its service.